Anti-angiogenesis approach to genitourinary cancer treatment - PubMed (original) (raw)

Anti-angiogenesis approach to genitourinary cancer treatment

Jeanny B Aragon-Ching et al. Update Cancer Ther. 2009.

Abstract

Angiogenesis plays a crucial role in the survival, proliferation, and metastatic potential of several tumors, including genitourinary (GU) cancers. Over the last decade, increasing basic science and clinical research have led to the approval of several angiogenesis inhibitors. GU tumors are unique in its pathogenesis whereby specific pathways, such as involvement of the Von Hippel-Lindau gene in clear cell renal cell cancer and aberrant overexpression of vascular endothelial growth factor in prostatic cancers and transitional cell bladder cancers, allow for potential targeting using angiogenesis inhibitors. This review discusses the biologic pathways as well as the rationale for using angiogenesis inhibitors in renal cell, prostate, and transitional cell bladder cancers. This review also focuses on pivotal trials and emerging data on the use of these inhibitors.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None to declare.

References

    1. Hall A. The role of angiogenesis in cancer. Comp Clin Path. 2005;13:95–99.
    1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6. - PubMed
    1. Folkman J. History of angiogenesis. In: Figg W, Folkman J, editors. Angiogenesis: an Integrative Approach From Science to Medicine. New York, NY: Springer Science; 2008. pp. 1–14.
    1. FDA Approval Summary for Bevacizumab - National Cancer Institute. [November 10, 2008]. http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab.
    1. Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev. 2007 - PubMed

LinkOut - more resources